96 related articles for article (PubMed ID: 33437948)
1. Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England.
Cherla A; Renwick M; Jha A; Mossialos E
EClinicalMedicine; 2020 Dec; 29-30():100625. PubMed ID: 33437948
[TBL] [Abstract][Full Text] [Related]
2. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
Thokala P; Carlson JJ; Drummond M
J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
[TBL] [Abstract][Full Text] [Related]
3. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
[TBL] [Abstract][Full Text] [Related]
4. CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER).
Langley PC
Innov Pharm; 2018; 9(4):. PubMed ID: 34007726
[TBL] [Abstract][Full Text] [Related]
5. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
Langley PC
Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
[TBL] [Abstract][Full Text] [Related]
6. Impact of Incorporating Future Mandatory Price Reductions with Generic Drug Entry on the Cost-Effectiveness of New Drugs: A Policy Simulation Study of Dupilumab in Atopic Dermatitis Treatment.
Kim M; Quan G; Noh Y; Hong SH
Healthcare (Basel); 2024 May; 12(9):. PubMed ID: 38727495
[TBL] [Abstract][Full Text] [Related]
7. Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience.
Langley PC
Innov Pharm; 2021; 12(1):. PubMed ID: 34007666
[TBL] [Abstract][Full Text] [Related]
8. How do the Institute for Clinical and Economic Review's Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee's Assessments of Added Benefit? A Qualitative Study.
DiStefano MJ; Pearson SD; Rind DM; Zemplenyi A
Value Health; 2024 Apr; ():. PubMed ID: 38679288
[TBL] [Abstract][Full Text] [Related]
9. The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies.
Langley PC
Innov Pharm; 2019; 10(3):. PubMed ID: 34007563
[TBL] [Abstract][Full Text] [Related]
10. Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments.
van Harten W; IJzerman MJ
Ecancermedicalscience; 2017; 11():ed71. PubMed ID: 28955404
[TBL] [Abstract][Full Text] [Related]
11. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.
Langley PC
Innov Pharm; 2020; 11(4):. PubMed ID: 34007652
[TBL] [Abstract][Full Text] [Related]
12. Systems, design and value-for-money in the NHS: mission impossible?
Young T; Morton A; Soorapanth S
Future Healthc J; 2018 Oct; 5(3):156-159. PubMed ID: 31098558
[TBL] [Abstract][Full Text] [Related]
13. Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the Institute for Clinical and Economic Review in Health Technology Assessment.
Langley PC
Innov Pharm; 2021; 12(2):. PubMed ID: 34345518
[TBL] [Abstract][Full Text] [Related]
14. Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?
Ghabri S
Pharmacoeconomics; 2024 May; ():. PubMed ID: 38733557
[No Abstract] [Full Text] [Related]
15. Real-World Evidence Studies in Oncology Therapeutics: Hope or Hype?
Thakur S
Indian J Surg Oncol; 2023 Dec; 14(4):829-835. PubMed ID: 38187834
[TBL] [Abstract][Full Text] [Related]
16. An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada.
Lewis D; Wong WWL; Lipscomb J; Horton S
Pharmacoeconomics; 2024 Apr; 42(4):393-407. PubMed ID: 38150120
[TBL] [Abstract][Full Text] [Related]
17. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting.
Russell-Smith A; Murphy L; Nguyen A; Blauer-Peterson C; Terpenning M; Cao F; Li S; Bancroft T; Webb N; Dorman S; Shah R
J Comp Eff Res; 2024 Feb; 13(2):e230142. PubMed ID: 38099517
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.
Davie A; Traoré S; Giovannitti M; Pompilio G; Lambton M; Cakar E; Chatterjee A
Glob Reg Health Technol Assess; 2023; 10():62-69. PubMed ID: 37811343
[TBL] [Abstract][Full Text] [Related]
19. Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey.
Richardson MT; Attwood K; Smith G; Liang SY; LaVigne Mager K; Tewari KS; Coleman RL; Kapp DS; Chan JK; Monk BJ
Cancer Control; 2023; 30():10732748231182795. PubMed ID: 37646470
[TBL] [Abstract][Full Text] [Related]
20. Quantitative cost‑effectiveness index of cancer treatments.
Wu Z; Yang Y; Chen D
Med Int (Lond); 2023; 3(2):17. PubMed ID: 37021300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
